Trial Profile
A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Jul 2023
Price :
$35
*
At a glance
- Drugs ONCOS 102 (Primary) ; Carboplatin; Cisplatin; Cyclophosphamide; Pemetrexed
- Indications Malignant-mesothelioma
- Focus Adverse reactions
- Acronyms MESOS
- Sponsors Targovax
- 06 Jun 2023 Results of granular analyses of individual immune-related gene expression in response to ONCOS-102 presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 10 Apr 2022 This trial has been completed in Spain (Global end date: 08-10-2019), according to European Clinical Trials Database record.